Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

Executive Summary

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

You may also be interested in...



Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Medtech Veteran Robert Ford Will Take Over As Abbott CEO From Miles White

Abbott’s current COO Robert Ford will become the company’s new CEO on 31 March, 2020. Miles White is stepping down after 21 years leading the diversified health-care products company.

Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific

Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel